Amgen (NASDAQ:AMGN) Versus Axcella Health (NASDAQ:AXLA) Head-To-Head Contrast
Amgen (NASDAQ:AMGN) Versus Axcella Health (NASDAQ:AXLA) Head-To-Head Contrast
Axcella Health (NASDAQ:AXLA – Get Rating) and Amgen (NASDAQ:AMGN – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.
安赛乐健康(纳斯达克：AXLA-GET评级)和安进(纳斯达克：AMGN-GET评级)都是医疗公司，但哪只股票更优越？我们将根据两家公司的股息实力、估值、分析师建议、风险、机构所有权、收益和盈利能力对它们进行比较。
Valuation & Earnings
估值与收益
This table compares Axcella Health and Amgen's gross revenue, earnings per share (EPS) and valuation.
此表比较了Axcell a Health和安进的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Axcella Health | N/A | N/A | -$64.63 million | ($1.66) | -0.38 |
| Amgen | $25.98 billion | 5.27 | $5.89 billion | $12.47 | 20.57 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| AXCELA健康 | 不适用 | 不适用 | -6,463万元 | ($1.66) | -0.38 |
| 安进 | 259.8亿美元 | 5.27 | 58.9亿美元 | $12.47 | 20.57 |
Amgen has higher revenue and earnings than Axcella Health. Axcella Health is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
安进的收入和收益比Axcell a Health更高。Axcell a Health的市盈率低于安进，这表明它目前是两只股票中更负担得起的一只。
Analyst Ratings
分析师评级
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Axcella Health | 0 | 2 | 2 | 0 | 2.50 |
| Amgen | 4 | 4 | 4 | 0 | 2.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| AXCELA健康 | 0 | 2 | 2 | 0 | 2.50 |
| 安进 | 4 | 4 | 4 | 0 | 2.00 |
Axcella Health presently has a consensus price target of $5.25, suggesting a potential upside of 733.33%. Amgen has a consensus price target of $253.57, suggesting a potential downside of 1.16%. Given Axcella Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe Axcella Health is more favorable than Amgen.
Axcell a Health目前的共识目标价为5.25美元，这意味着潜在的上涨幅度为733.33。安进的普遍目标价为253.57美元，这意味着潜在的下跌幅度为1.16%。考虑到Axcell a Health更强劲的共识评级和更高的可能上行空间，股票研究分析师显然认为Axcell a Health比Amgen更有利。
Volatility and Risk
波动性和风险
Axcella Health has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
Axcell a Health的贝塔系数为1.19，表明其股价的波动性比标准普尔500指数高出19%。相比之下，安进的贝塔系数为0.67，这表明其股价的波动性比标准普尔500指数低33%。
Profitability
盈利能力
This table compares Axcella Health and Amgen's net margins, return on equity and return on assets.
此表比较了Axcell a Health和安进的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Axcella Health | N/A | -567.25% | -147.10% |
| Amgen | 25.96% | 287.23% | 16.16% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| AXCELA健康 | 不适用 | -567.25% | -147.10% |
| 安进 | 25.96% | 287.23% | 16.16% |
Insider and Institutional Ownership
内部人与机构持股
71.1% of Axcella Health shares are owned by institutional investors. Comparatively, 75.5% of Amgen shares are owned by institutional investors. 6.5% of Axcella Health shares are owned by company insiders. Comparatively, 0.5% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Axcella Health 71.1%的股份由机构投资者持有。相比之下，安进75.5%的股份由机构投资者持有。Axcell a Health 6.5%的股份由公司内部人士持有。相比之下，安进0.5%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、大型基金管理公司和对冲基金相信，一只股票有望实现长期增长。
Summary
摘要
Amgen beats Axcella Health on 9 of the 13 factors compared between the two stocks.
安进在比较两只股票的13个因素中有9个超过了Axcella Health。
About Axcella Health
关于Axcella Health
(Get Rating)
(获取评级)
Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
Axcell a Health，Inc.是一家生物技术公司。它从事疾病治疗的研究和开发，并使用内源性代谢调节剂或EMM及其组合物改善健康。其产品线包括用于降低复发临床肝性脑病风险的AXA1665和用于非酒精性脂肪性肝炎的AXA1125。该公司由Noubar B.Afeyan、Geoffrey von Maltzahn和David A.Berry于2008年8月27日创立，总部设在马萨诸塞州剑桥市。
About Amgen
关于安进
(Get Rating)
(获取评级)
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
安进公司是一家生物技术公司，从事人类疗法的发现、开发、制造和营销。其产品包括以下品牌：Aranesp、Aimovig、Kanjinti、EVENITY、AMGEVITA、AVSOLA、BLINCETO、MVASI、Corlanor、Enbrel、Epogen、Imlyic、Kyprolis、Neulasta、NEUPOGEN、NPLATE、Parsabiv、Prolia、Repatha、Sensiar、Vectibix、Otezla、RIABNI和XGEVA。该公司由小威廉·K·鲍斯、小富兰克林投手约翰逊、乔治·B·拉特曼和约瑟夫·鲁宾菲尔德于1980年4月8日创立，总部设在加利福尼亚州千橡市。
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Axcell健康日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Axcella Health和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。